Showing 73 to 84 of 116 results
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
Progress
56% Bias Score
Ozempic Shows Promise in Treating Alcohol Addiction
A new study published in JAMA Psychiatry shows that Semaglutid, the active ingredient in Ozempic, significantly reduced alcohol cravings and consumption in 48 participants with alcohol use disorder over nine weeks, suggesting a potential new treatment for alcohol addiction.
Ozempic Shows Promise in Treating Alcohol Addiction
A new study published in JAMA Psychiatry shows that Semaglutid, the active ingredient in Ozempic, significantly reduced alcohol cravings and consumption in 48 participants with alcohol use disorder over nine weeks, suggesting a potential new treatment for alcohol addiction.
Progress
40% Bias Score
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
Wegovy Approved for Heart Disease Treatment in Australia
Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.
Wegovy Approved for Heart Disease Treatment in Australia
Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.
Progress
36% Bias Score
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
Progress
40% Bias Score
Afghan Man Loses 125kg to Attend University
A 216kg Afghan man, Powerullah, lost 125kg in 10 months through a strict diet and intense exercise regime to attend university, overcoming health issues, social stigma, and mobility challenges.
Afghan Man Loses 125kg to Attend University
A 216kg Afghan man, Powerullah, lost 125kg in 10 months through a strict diet and intense exercise regime to attend university, overcoming health issues, social stigma, and mobility challenges.
Progress
36% Bias Score
Brain's Reward System Drives Excessive Sugar Consumption
A study using mice and human brain tissue found that high-sugar diets activate POMC neurons, releasing beta-endorphin, an endogenous opioid, which triggers a reward response, driving increased consumption. This mechanism was also observed in humans using fMRI.
Brain's Reward System Drives Excessive Sugar Consumption
A study using mice and human brain tissue found that high-sugar diets activate POMC neurons, releasing beta-endorphin, an endogenous opioid, which triggers a reward response, driving increased consumption. This mechanism was also observed in humans using fMRI.
Progress
12% Bias Score
Ramadan Fasting: Short-Term Effects and Long-Term Adaptation
Millions of Muslims fast during Ramadan, abstaining from food and drink from dawn to dusk for 30 days. The body initially uses stored glucose, then fat, potentially leading to weight loss and improved health, but also causing initial side effects like weakness and headaches. Adaptation occurs over t...
Ramadan Fasting: Short-Term Effects and Long-Term Adaptation
Millions of Muslims fast during Ramadan, abstaining from food and drink from dawn to dusk for 30 days. The body initially uses stored glucose, then fat, potentially leading to weight loss and improved health, but also causing initial side effects like weakness and headaches. Adaptation occurs over t...
Progress
40% Bias Score
Avoiding Glucose Spikes for Weight Loss: A Dietary Strategy
Avoiding rapid spikes in blood glucose, achieved by combining carbohydrates with fiber and protein, prevents excess sugar from being stored as fat, aiding weight loss and reducing long-term health risks like hypertension.
Avoiding Glucose Spikes for Weight Loss: A Dietary Strategy
Avoiding rapid spikes in blood glucose, achieved by combining carbohydrates with fiber and protein, prevents excess sugar from being stored as fat, aiding weight loss and reducing long-term health risks like hypertension.
Progress
44% Bias Score
GLP-1 Drugs: Reshaping Beauty Standards and Social Status
The increasing availability of GLP-1 weight-loss drugs is disrupting traditional beauty standards, potentially diminishing the status associated with thinness and prompting the affluent to seek new markers of distinction.
GLP-1 Drugs: Reshaping Beauty Standards and Social Status
The increasing availability of GLP-1 weight-loss drugs is disrupting traditional beauty standards, potentially diminishing the status associated with thinness and prompting the affluent to seek new markers of distinction.
Progress
52% Bias Score
Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Ozempic and Wegovy May Reduce Risk of Multiple Diseases: Large-Scale Study
A study of 1.2 million veterans' health records suggests that Ozempic and Wegovy, GLP-1 receptor agonists, may reduce risks of schizophrenia, Alzheimer's, and substance abuse, although further research is needed due to the study's limitations.
Progress
52% Bias Score
Fat Cell Memory Explains Weight Regain After Dieting
A Nature study reveals that fat cells 'remember' being fat, making weight loss difficult; 90% of dieters regain weight due to epigenetic changes in fat cells that persist even after weight loss, highlighting the need for long-term lifestyle changes for sustainable weight management.
Fat Cell Memory Explains Weight Regain After Dieting
A Nature study reveals that fat cells 'remember' being fat, making weight loss difficult; 90% of dieters regain weight due to epigenetic changes in fat cells that persist even after weight loss, highlighting the need for long-term lifestyle changes for sustainable weight management.
Progress
40% Bias Score
Showing 73 to 84 of 116 results